Search results
Biotech Stock Roundup: BIIB's Acquisition, PTCT, LRMR Gain on Updates & More News
Zacks via Yahoo Finance· 1 day agoThis decision was based on top-line data from the phase I/II ALSpire study, wherein treatment with...
BIIB INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Biogen Inc. Investors with...
WPRI Providence· 18 hours ago("Biogen Inc." or "the Company") (NASDAQ: BIIB) and certain of its officers. This lawsuit seeks to recover damages against Defendants for alleged violations of the federal ...
Biogen Inc. (NASDAQ:BIIB) Shares Sold by Dai ichi Life Insurance Company Ltd
ETF DAILY NEWS· 12 hours agoDai ichi Life Insurance Company Ltd lessened its holdings in shares of Biogen Inc. (NASDAQ:BIIB – Free Report) by 47.1% during the fourth quarter, according to its most recent ...
Needham & Company LLC Reiterates “Buy” Rating for Biogen (NASDAQ:BIIB)
ETF DAILY NEWS· 18 hours agoBiogen (NASDAQ:BIIB – Get Free Report)‘s stock had its “buy” rating restated by Needham & Company LLC in a report issued on Wednesday, Benzinga reports. Needham & Company ...
Gainey McKenna & Egleston Announces a Class Action Lawsuit Has Been Filed Against Biogen, Inc. (BIIB...
Morningstar· 1 day ago(“Biogen” or the “Company”) (NASDAQ: BIIB) between February 3, 2022 and February 13, 2024, inclusive (the “Class Period”). The Complaint further alleges that on November 8 ...
Pomerantz Law Firm Announces the Filing of a Class Action Against Biogen Inc. and Certain Officers -...
Morningstar· 2 days agoPomerantz LLP announces that a class action lawsuit has been filed against Biogen Inc. ("Biogen" or the"Company") (NASDAQ: BIIB) and certain officers. The class action, filed ...
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Biogen Inc. with Losses to...
WKRN Nashville· 23 hours agoThe Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class...
IGM Biosciences stock surges as Biogen's deal for HI-Bio is seen as a positive By Investing.com
Investing.com· 2 days agoIGM Biosciences stock surges as Biogen's deal for HI-Bio is seen as a positive
Biogen to buy San Francisco startup developing a drug for kidney disease for $1.2B - Boston Business...
The Business Journals· 2 days agoBiogen Inc. is shelling out $1.15 billion upfront to buy a South San Francisco immunology company....
Larimar (LRMR) Up on Lifting of Partial Clinical Hold on FA Study
Zacks· 3 days agoFree Report) announced that the FDA has removed the partial clinical hold on its nomlabofusp (CTI-1601) clinical program following a review of the phase II dose exploration study data. Shares ...